LOOK AT THE
Enterome and Gustave Roussy enter into a microbiome-based collaboration to develop novel immunotherapy solutions to treat cancer
Enterome is a Paris-based private company with advanced technology and products in the emerging field of disease management of the human gut microbiome. Enterome has recently opened a subsidiary in Cambridge (MA).
Our company has been established in 2012 and has already raised a €17.5m in two rounds with private equity funds (Seventure, Omnes Capital, Lundbeckfond Ventures, Health for Life Capital) and strategic investors (INRA Transfert & Shire).
Enterome is developing innovative therapeutic solutions in the new and promising field of diseases associated with abnormalities of the gut microbiome and that are as diverse as Crohn’s disease, asthma, obesity, diabetes, multiple sclerosis, and some forms of cancers.
VP M&A and business development at Sanofi Ophthalmology, Pierre was the founder and COO of Fovea Pharmaceuticals and has been instrumental in building up the product-portfolio that became the Ophthalmology division of Sanofi (Fovea was acquired by sanofi in 2009 for €370m, less than five years after inception). Earlier, Pierre was VP Business Development at UroGene, a company sold to Pierre Fabre in 2004. In 2000, he took over the position of head of European commercial operations at Ethypharm. Prior to this, Pierre held various positions in science and business development at Fournier Pharma. Pierre is PharmD, PhD and holds a MBA from INSEAD.
Business Development & Contract Manager at Sanofi, Marie-Laure joined Fovea Pharmaceuticals at inception as Business Development associate and has been involved in all licensing and contractual operations of the company from founding to trade sale to Sanofi. Earlier, Marie-Laure has been Business Development associate at UroGene.
Before joining Enterome, Rodolphe Clerval was VP Corporate and Business Development of TcLand Expression, a molecular diagnostic company. During his tenure with TcLand Expression, he led strategic planning activities and closed several collaborations and licensing deals. Previously he was Business Development Manager at Genzyme. Prior to this he was financial analyst for the brokerage firm Natixis Bleichroeder. Earlier in his career, Rodolphe served as Research Scientist at Aventis Animal Nutrition.
Jean-Michel has more than 20 years expertise in clinical development plan design from phase I to IV and writing of key regulatory documents. He has an international and wide range of experiences in various company types from biotech (Ablynx, AB Science, Diatos) to major pharmaceutical companies (Glaxo, Eli Lilly, Sanofi) and Clinical Research Organisations (Harrison Clinical Research).
Bertrand Lellouche has joined Enterome in 2015. Previously he served as Group Finance Director at Prunay, where he has developed, structured and consolidated financial departments. He was also in charge of Prunay Services, the group shared services he had created. From 2001 to 2010, he has operated as VP – CFO within fast growing innovative groups, such as SpineGuard, NetASQ and Theradiag, leading and preparing them to 2 IPOs or acquisition. He has started his career by Technomed, Coflexip (Technip) and Vivendi (Veolia) holding financial executive positions and participating to their large developments, including IPOs and M&A operations. Bertrand holds a Master of Science in International Management from the MBA Institute.
HEAD OF DRUG DISCOVERY
Laurent joined Enterome in January 2015 with more than 15 years of experience in target identification and drug discovery. He obtained his PhD in Pasteur Institute, working on HIV in the F. Barre Sinoussi Lab. He next started his carrier in Industry in 2001 working in medium biotech as UroGene or Inventiva and in larger groups as Fournier, Solvay and Abbott. During these years, he was in charge of medium throughput screening platforms dedicated to genomic and transcriptomic analysis. He was also project leaders on several preclinical targets in a large range of therapeutic area as metabolic disorders, oncology, inflammatory diseases and CNS disorders.
HEAD OF BIOMARKER DISCOVERY
Alessandra joined Enterome in March 2014 where she is leading the biomarker discovery and development activities. She has developed and industrialized the first full quantitative metagenomics pipeline to translate metagenomics research into diagnostics. Prior to joining Enterome she was CSO of Tcland Expression, Assistant Professor at Scripps Florida and senior research scientist at Merck & Co. She has been awarded honorary positions in US and UK academia (Research Professorship at Florida Atlantic University and Senior Lectureship at King’s College London) and is the founder to Luxia Scientific, a consulting firm specialized in advising investment funds. Alessandra holds a DPhil from the University of Oxford in Clinical Medicine and an MSc in Biometry.
Research director at INRA, Dusko is leader the MetaGenoPolis initiative (French national Metagenomic plateform). Author or co-author of more than 350 publications in scientific journals and books, he is regularly invited in scientific symposia and is a frequent speaker in international conferences held in Europe, USA, Japan. He is coordinator of numerous international (EU, USA, Japan and China) collaborative programs, MetaHIT in particular. Dusko has active collaborations with international companies (Pfizer, Danone, BioMérieux,BGI, …)
Georges has over 25 years of experience in the pharmaceutical industry, including management and executive positions in the US, Europe and the Middle East. He currently serves on the board of directors of US publicly-traded companies Supernus Pharmaceuticals, Inc. and Raptor Pharmaceutical Corp., and is the Chairman of the boards of OxThera AB, EpiTherapeutics ApS and Orphazyme ApS.
From 2008 to 2009, Dr Gemayel was President and Chief Executive Officer of Altus Pharmaceuticals Inc., a publicly-traded pharmaceutical company. From 2003 to 2008, he was Executive Vice President at Genzyme Corporation where he was responsible for the company’s global therapeutics, transplant, renal and biosurgery businesses. From 1998 to 2003, he held progressively senior roles at Hoffmann La-Roche and Roche Labs, most recently as Vice President, National Specialty Care, responsible for its US business for dermatology, oncology, transplantation, hepatitis and HIV.
Founder and CEO at Fovea Pharmaceuticals from 2005, Bernard has led the trade sale to Sanofi in 2009 and is now head of the Sanofi Ophthalmology division. Bernard has been a partner at Sofinnova Partners from 2000 to 2005. Earlier, Bernard was president and CEO of Transgene from its early financing round in 1994 to its listing on the Nasdaq and Nouveau Marché in 1998. Prior to joining Transgene, he spent 6 years as VPR&D at Pasteur-Merieux Connaught
Pierre has over 25 years’ experience in leading organizations and high-growth-potential start-ups through the development and launch of innovative tests and high-science clinical diagnostic solution. He is currently President and Chief Executive Officer at NMS Labs. Before this, he was CEO at Molecular Diagnostic LTD, President and CEO, XDX Inc. Earlier, Pierre was VP Diabetes Management, Becton Dickinson, Senior VP Business Operations, Bayer US and BU General Manager, J&J.
Felix is a respected thought leader in personalized medicine with nearly twenty years of R&D, management and policy experience. He is currently CSO at Human Longevity Inc. He was also Manager in residence at Third Rock and President, Medco Research Institute at Medco Health Solutions, Inc. (now Express Scripts). Earlier, Felix was Associate Director for Genomics at FDA/CDER/Office of Clinical Pharmacology (OCP) and Research Director, Pharmacogenetics at Transgenomic.
Being one of the leading venture capital firms in Europe, Seventure manages €500m and invests since 1997 in innovative businesses with high growth potential in IT and in Life Sciences. With preferred sectors of Biotech & Pharmaceuticals, Medtech, Industrial Biotech & Cleantech, and Lifestyle Healthcare & Nutrition. Seventure is a subsidiary of Natixis.
Lundbeckfond Ventures is an life science venture fund established in 2009 and wholly owned by the Lundbeck Foundation. On an annual basis, Lundbeckfond Ventures invests up to € 50 million. Investments are made within lifescience, focusing on pharmaceuticals and biopharmaceuticals, medtech, diagnostics and healthcare service companies.
Omnes Capital is a major player in private equity, with a commitment to financing SMEs. With €2.1 billion in assets under management, Omnes Capital provides companies with the capital needed to finance their growth. Omnes Capital, formerly Crédit Agricole Private Equity, was a subsidiary of Crédit Agricole until March 2012 when the company was acquired by Coller Capital.
Shire is a pharmaceutical company formed 25 years ago and focusing on developing treatments for conditions in a large range of domains like CNS, Gastrointestinal, Orphan genetic diseases, Allergy and Hematology. In 2011, the company’s revenue was USD 4.3 billion. Shire has committed initial capital funding of $50 million to establish a Strategic Investment Group. Shire co-invests via the SIG as part of a syndicate.
Health for Life Capital supports innovative high-growth entrepreneurial ventures. Geographically, its focus is primarily in Europe, but also extends to North America and Asia. Investments will be made in the areas of healthcare, life sciences, biotechnology, medical technologies, pharmaceuticals, nutrition and in the emerging fields of microbiome and connected health.
Enterome has been created in 2012 to develop products from the scientific results obtained in the gut microbiome space by the French National Institute of Agronomy Research (INRA, Paris). Dusko Ehrlich and his team have been pioneers in the measurement and modulation of gut microbiome’s role in health and diseases. This field has emerged as one of the newest and most promising field of medical sciences.
Enterome uses two different platforms :
- A QUANTITATIVE METAGENOMICS PLATEFORM based on full sequencing and mapping of total fecal bacterial gene content that allows the characterization of a personal metagenome (metagenotype®) associated with a disease phenotype. This technology enables the identification of biomarkers and of bacteria of interest associated with the development of diseases.
- A FUNCTIONAL METAGENOMICS PLATEFORM based on the screening of genomic or metagenomics libraries on cell based assays and on specific pathways of interest that allows the discovery and the development of news drugs and targets.
The overall Crohn’s Disease (CD) market will increase from approximately $3.8 billion in 2011 to $5.6 billion in 2021. The specialty GI category is growing faster than any other therapeutic area (Evaluate Pharma – 2014)
In 2011, in US and EU, CD prevalence is estimated around 1 million patients, among them 500 000 patients are currently under medication for treating moderate-to-severe form of the disease. This figure will outpace 600 000 moderate-to-severe patients by 2020 (Datamonitor – 2014).
Current medical treatment of CD consists of immunosuppressive drug therapy (corticosteroids, azathioprine, methotrexate, anti-TNF monoclonal antibodies). These agents control symptoms of CD in most patients, but their withdrawal leads to disease relapse. They are also associated with serious side effects (infections, lymphoma, cancers, liver toxicity). Anti-TNF monoclonal antibodies are the most efficacious but are cost prohibitive. Moreover, each year, roughly 10% of responders to anti-TNF become refractory to treatment, most often because they become tolerized to these drugs. Future CD drugs are small molecules or biologics that antagonize proinflammatory cytokines or gut homing of lymphocytes. Yet, they have similar safety issues as the immunosuppressive agents currently in use.
The current therapeutic algorithm for CD does not take into account the site of inflammation or composition of intestinal microbiome. Moreover, dysregulated intestinal immunity and overproduction of proinflammatory cytokines are not the only components of CD pathophysiology. Intestinal microbiome is abnormal and plays an important role in the pathogenesis of CD.
In order to prepare the next generation of IBD drugs, Enterome is leading a discovery program of novel products originating from the gut microbiome with its high throughput discovery platform. Metagenomic/genomic libraries have been developed to identify active commensal derived molecules with regulatory functions and among them, new compounds for therapeutic purpose or new targets/pathways for drug discovery programs.
IBD110 is the first noninvasive gut microbiome biomarker surrogate marker of mucosal healing.
It has initially been identified in a 100 patient longitudinal cohort of Crohn’s disease (CD) patients and further validated in an independent international cohort of 300 CD patients in collaboration with AbbVie.